Kornimate/medical-research-clean huggingface dataset:
intestinal parasites in inhabitants of kuyavian-pomeranian province in poland

Conditions: Intestinal Disease, Parasitic; Chronic Disease

Summary: the goal of the proposed study is to assess the prevalence of intestinal parasitic diseases in adults and children. these invasions are included to "dirty hand diseases" (per os invasions), therefore it applies mainly preschool children.

it is estimated that 75% of the world's population is infected with parasites and although parasitic diseases are mostly observed in the poor tropical and subtropical countries, there are also many diseases caused by parasites in poland. in poland, particular attention is paid to the following parasitic diseases closely related to the digestive system: giardiasis, taeniasis (including cysticercosis), ascariasis, cryptosporidiosis, toxoplasmosis, trichinosis, echinococcosis. symptoms of such invasions may include: allergic rhinitis of unknown origin, chronic fatigue or food intolerance. moreover, many of them are asymptotic, therefore the study group will consist of both healthy people and individuals with undiagnosed diseases or/and chronic symptoms.

Eligibility criteria:
inclusion criteria: * healthy and ailing individuals * men and females * adults and children exclusion criteria: * the participants were not be: incapacitated persons, soldiers, prisoners and persons dependent in any way from the investigators

Keywords: per os invasions giardiasis toxoplasmosis taeniasis cryptosporidiosis trichinosis ascariasis echinococcosis
safety and efficacy study of topic mucopolysaccharide polysulfate cream in the superficial varicose veins treatment

Conditions: VARICOSE VEINS

Summary: evaluate the safety, tolerability and effectiveness of mucopolysaccharide polysulfate cream in the treatment of superficial varicose veins


Eligibility criteria:
inclusion criteria: * patients must be able to understand the study procedures, agree to participate, and give written consent. * patients must be able to follow the study medication regimen. * patients with inflammatory process in superficial veins for more than 72 hours. * presence of symmetric lesions to compare one side to the other. exclusion criteria: * pregnancy or risk of pregnancy. * lactation. * use of topical or systemic anti-inflammatory, antihistamine or immunosuppressive drugs within the last 48 hours prior to the study * any alteration at other deep veins. * history of atopy or allergic diseases. * history of allergy to any component of the formulations. * other conditions considered by the investigator as reasonable for non-eligibility

Keywords: superficial varicose veins
neoadjuvant endostatin and chemotherapy for breast cancer

Conditions: Breast Cancer

Summary: this study was designed to determine the efficacy and safety of neoadjuvant docetaxel and epirubicin (de) with or without human recombinant endostatin (endostar) for breast cancer patients. the hypothesis of this protocol is that a combined angiogenesis inhibiting therapy to chemotherapy could further enhance the cytotoxic activity in breast cancer.

this is an open labelled, prospective, randomized, phase ii clinical trial. a total of 60 patients with core-biopsy confirmed breast cancer, stage ⅱa to ⅲc, and to be treated with neoadjuvant systemic therapy are eligible for entry into this study. patients will be allocated randomly to two groups to receive either 3 cycles of neoadjuvant de and endostar or 3 cycles of neoadjuvant de. all cases receive mammography, contrast-enhanced ultrasound (ceus), magnetic resonance angiography (mra), and positron emission tomography (pet) scanning pre- and post-neoadjuvant therapy, and then undergo surgical resection. the primary endpoint is clinical/pathological response. the secondary endpoint is (1) the safety and tolerability of the regimens, (2) the role of mammography, ceus, mra and pet for response evaluation, and (3) angiogenic profile and biological information involved in tumor response.

Eligibility criteria:
inclusion criteria: * histologically confirmed invasive breast cancer (core needle biopsy for breast cancer diagnosis and fine needle aspiration for lymph node metastasis diagnosis) * stage ⅱa-ⅲc * age 18-70 * ecog performance status 0-2 * no evidence of distant metastasis * no previous therapy * normal hematologic function * left ventricular ejection fraction greater than 50 percent * no abnormality of renal or liver function * written informed consent exclusion criteria: * with allergic constitution or possible allergic reflection to drugs to be used in this study * any concurrent uncontrolled medical or psychiatric disorder * history of severe heart diseases, including congestive heart failure, unstable angina, uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood pressure, or heart valve disease. * history of bleeding diathesis * being pregnant or nursing

Keywords: breast cancer neoadjuvant chemotherapy docetaxel epirubicin recombinant human endostatin (endostar) chemotherapy endostatin
capecitabine and radiation therapy in advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: pancreatic cancer has traditionally been treated with chemotherapy and radiation therapy with limited results. preliminary studies of parts of this program in patients with advanced pancreatic cancer have produced favorable results with acceptable side effects. we feel that this treatment sequence may help to slow and/or control the growth of pancreatic cancer. this study will help doctors learn whether pancreatic cancer will respond to this treatment. this study will use the combination of two chemotherapy drugs, gemcitabine and cisplatin, before and after treatment with radiation therapy and an oral chemotherapy drug called capecitabine. this sequence of combination chemotherapy before and after radiation therapy, and radiation therapy with the drug capecitabine is what is under study. parts of this sequence, for example, the combination of gemcitabine and cisplatin, have shown promising results in the treatment of pancreatic cancer. this research study is an attempt to combine these various parts.


Eligibility criteria:
eligibility criteria 1. patients must have cytologic or histologic confirmation of pancreatic carcinoma. 2. patients must have unresectable disease with or without distant metastases. a status of unresectable will be based on review of helical ct scan and surgical consultation. 3. patients with a history of previous abdominal irradiation or chemotherapy for pancreatic cancer are ineligible. 4. patients must have an estimated life expectancy of at least 12 weeks and a zubrod performance status of ≤ 2 (appendix i). 5. patients must be 18 years of age or older. patients with reproductive potential must agree to use an effective contraceptive method during treatment. 6. patients must have adequate organ function defined as follows: bone marrow - granulocytes ≥ 1500/cmm, platelets \> 100,000/cmm, renal - serum cre \< 1.5 mg/dl, hepatic - bilirubin \< 3 mg/dl. 7. patients must be free of other active systemic malignancy or any other serious co-morbid medical or psychiatric condition that would interfere with safe delivery of protocol therapy. 8. patients must be aware of the investigational nature of the therapy and provide written informed consent as per institutional guidelines prior to the initiation of treatment.
total body composition in detection of nutrition depletion in head and neck patients

Conditions: Head and Neck Neoplasms; Dual-Energy X-Ray Absorptiometry; Malnutrition

Summary: the purpose of this study is to define the role of total body composition in the guidance of nutritional support and treatment monitoring in head and neck patients. furthermore, the second aim of this study is to compare the clinical performance of dual energy x-ray absorptiometry as compared to ct in evaluating total body composition of patients.

in this 4-year cohort study, a total of 120 patients with stage iii-iv head and neck cancer (squamous cell carcinoma) patient undergoing concurrent chemo-radiotherapy will be enrolled. laboratory examination will be performed to evaluate the physiological change and treatment related toxicity, including bun and cr for hydration and renal function; complete blood cell and differential count, pre-albumin and albumin for nutrition, and c-reactive protein for inflammatory change. both ct and dual energy x-ray absorptiometry (dxa) will be used to evaluate total body composition. ct is used to evaluate surface area of fat and muscle, and dxa is used to evaluate lean body mass, fat body mass and bone mineral content. mri of the head and neck region is used for tumor staging of the head and neck cancer, monitoring the treatment response and detecting treatment related adverse effect.

Eligibility criteria:
inclusion criteria: 1. biopsy-proven head and neck (scc), surgery of the primary tumor/lymph nodes is limited to incisional/excisional biopsy. 2. 2010 7th edition ajcc stage iii, iva (t4n0-2) and ivb (any t, n3). 3. well-informed and accepted treatment of ccrt. 4. age 20-70 years old. 5. negative pregnancy test for women of childbearing potential. 6. adequate hematopoietic or organ function which is amenable for chemotherapy: * a leukocyte count ≥3000/l * platelet count ≥100,000/l. * serum bilirubin level ≦ 1.5mg/dl * serum creatinine level ≦1.6 mg/dl or creatinine clearance ≥ 60 ml/min/1.73 m2. * alt/ast ≦ 3x uln 9. ability to understand and willingness to be enrolled in our study and sign a written informed consent document exclusion criteria: 1. npc is excluded from this study. 2. patients have acute medical conditions (such as bacterial or viral infection or active cardiopulmonary disease) that may be incapable of having regular image study. 3. patients are under regular steroid or hyperthyroid medications, which may have great impact on the whole body metabolism. 4. patients are under-nutrient and they need to have regular liquid oral nutrition formulas support. 5. patient that have dementia or pregnant. 6. patients not expecting to comply with follow up. 7. patient not suitable for chemotherapy. 8. patient not suitable for mri, such as claustrophobia, previous metal implantation, previous cardiac pacemaker implantation, inability to comply with mri instructions and poor renal function. 9. received barium study within a week.

Keywords: head and neck neoplasms total body composition dual-energy x-ray absorptiometry malnutrition muscle quantification
collaborative assessment of pediatric transverse myelitis: understand, reveal, educate or capture study

Conditions: Myelitis, Transverse; Flaccid Paraplegia, Complete, Acute; Flaccid Paraplegia, Incomplete, Acute

Summary: patients and families are invited to participate in an online registry and data repository specifically for patients with transverse myelitis (tm) or acute flaccid myelitis (afm). the data generated in this study will come from surveys, interviews, review of medical records. data from this study will be utilized to guide future clinical trials for children with an acute case of tm or afm. parents and school aged children will complete an online survey 7 banks of questions. each bundle of survey topics have 7-10 questions. we will have both the parent and child complete a outcomes based survey within 6 months of diagnosis and invite to participate every 4 months until study end in 2024.

both parent and child will participate in the online questionnaires. the validated questionnaires, promis or patient-reported outcomes measurement information system, are blocks of 8-10 questions. 7 blocks of questions for the parent and 7 similar blocks for the child: anxiety, depressive symptoms, fatigue, mobility, pain interference, peer relationships, upper extremity function. participation via the internet: when a child or family enters the transverse myelitis association (tma) website, they will be directed to information about the capture study. if the family is interested in participation, the tma will give them the ut southwestern in dallas, tx research coordinator information. it is up to the parent/guardian to contact the study staff from university texas southwestern. once initial contact is complete, at the family's request, study staff will send the consent form to the interested family. the family will need to email or mail the consent back. once the signed consent form is in hand, we will send the research survey to the email the parent provides. one survey for the parent, a separate but similar survey for a school aged child. we will invite parents of school aged children to complete a school survey. this is a one time only questionnaire. ideally, the parents will complete this either 6 months or 1 year into their child's recovery of tm/afm. we invite families living outside of north america to participate in the online survey. they need to be fluent in english, same as the north american cohort.

Eligibility criteria:
inclusion criteria for the registry: * diagnosis of transverse myelitis (tm) or acute flaccid myelitis (afm) * patient is within 6 months of symptom onset * ability of patent or legal guardian is able to provide informed consent * ability of a child 10 or older able to provide assent * access to the internet exclusion criteria for the registry: * inability to provide appropriate consent or assent * diagnosis of multiple sclerosis, neuromyelitis optica, or neuromyelitis optica spectrum disorder

Keywords: pediatrics
a study to evaluate camrelizumab combined with famitinib as subsequent therapy in patients with advanced nsclc

Conditions: Advanced NSCLC

Summary: this is a randomized, open-label, international, multi-center, phase iii trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in advanced nsclc.


Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed metastatic or recurrent non-small cell lung cancer. 2. failed previous platinum-based chemotherapy and anti-pd-(l)1 monoclonal antibody treatment. 3. have measurable disease based on recist v1.1. 4. ecog ps score: 0-1. 5. expected survival ≥ 3 months. 6. non-surgically sterilized female subjects or women of childbearing potential must be negative for a serum pregnancy test within 3 days prior to the first dose and must be non-lactating. female subjects of childbearing potential and male subjects with partners of childbearing potential must agree to take highly effective contraceptive measures during the study period and until 6 months after the last study dose. 7. subjects must participate voluntarily, sign the icf, have good compliance, and cooperate with follow-up visits. exclusion criteria: 1. have uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or ascites. 2. have known history of prior malignancy in the past 3 years. 3. have active pulmonary tuberculosis. 4. have clinical symptoms of the heart or heart diseases that are not well controlled. 5. have hypertension which cannot be well controlled by antihypertensives 6. urinalysis has indicated that the urine protein is ≥ ++ and quantitative test of urine protein has confirmed that the 24-h urine protein is \> 1.0 g. 7. have a thrombosis tendency or are currently receiving thrombolysis/anticoagulation therapy. 8. have received major surgery within 4 weeks prior to randomization; or palliative radiotherapy within 2 weeks prior to randomization; or have not recovered from the toxicities and/or complications of previous interventions to nci-ctcae grade ≤ 1. 9. have known history of arterial/venous thrombosis within 6 months prior to randomization, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism. 10. are currently participating and receiving study therapy or have participated in a study and received the last dose of study drug within 4 weeks (or 5 half-lives of the study drug) prior to randomization. 11. previous treatment with camrelizumab, docetaxel, and small-molecule vegfr inhibitors including famitinib. 12. have other potential factors that may affect the study results or result in the premature discontinuation as determined by the investigator.
efficacy of motilitone on gastric accommodation in healthy adult patients: evaluation using mri method

Conditions: Dyspepsia

Summary: functional dyspepsia (fd) is a disorder characterized by chronic or recurrent upper abdominal pain or discomfort in the absence of a specific structural cause. improving gastric accommodation and prokinetic effect seem to be an attractive physiological target in patients with fd. motilitone (dong-a st, yongin, korea) is a new herbal drug that was launched in december 2011 in korea for treating patients with fd. the current study aims to evaluate effects of motilitone on gastric accommodation and emptying after a meal in a group of healthy volunteers using three-dimensional gastric volume measurements by magnetic resonance imaging (mri). healthy volunteers are randomly allocated to receive either motilitone or placebo in a double blinded manner. after 5 days of treatment, subjects undergo gastric mri. the primary endpoint is gastric accommodation.


Eligibility criteria:
inclusion criteria: * healthy volunteers between 20 and 70 years of age without upper abdominal pain or discomfort and a structural abnormality on upper gastrointestinal (gi) endoscopy performed within the preceding 6 months were eligible for the trial. exclusion criteria: * patients were excluded if they met any of the following criteria: 1. any functional gi disease or previous abdominal surgery 2. diabetes mellitus under insulin or oral anti-hyperglycemic agent treatment 3. significant cardiopulmonary diseases or any malignancies 4. significant renal (serum creatinine level ≥ 1.5 × the upper normal limit) or liver disease (serum aspartate aminotransferase and alanine aminotransferase levels ≥ 2.5 × the upper normal limits 5. taking medications that may alter gastric function within 2 weeks prior to the start of the study 6. pregnancy or lactation 7. females with inadequate contraception during the study period 8. contraindications to mri (e.g., cardiac pacemaker or metallic aneurysm clip) 9. allergic history to motilitone 10. other conditions likely to interfere with study procedures, as judged by the investigator

Keywords: accommodation, emptying, motilitone
brain activity during sexual behavior in patients with primary premature ejaculation a clinical trial

Conditions: Premature Ejaculation

Summary: this is a controlled study of patients with and without primary premature ejaculation. it is based on near-infrared spectroscopy (nirs) functional brain imaging to detect and compare changes in brain activity in resting and task states (simulated sex) between the two groups of patients.


Eligibility criteria:
inclusion criteria (primary premature ejaculation subjects): * patients' age varied from 18 to 45 years； * patients met the 2014 international society for sexual medicine (issm) definition criteria for ppe； * patients had a stable, heterosexual relationship with a single sexually active female partner for at least 6 months and with at least two sexual intercourses a week and kept stable during the study period; * patients with premature ejaculation lasting longer than 6 months； * patients were identified if their scores were higher than 9 on the chinese version of premature ejaculation diagnostic tool (pedt); * patients had no history of any previous therapies for pe or had recently stopped the therapies for at least 3 months * patients had fully informed consent, signed informed consent form inclusion criteria (non-premature ejaculation subjects): * men between the ages of 18-45 years were included according to an age difference of \<3 years between each patient and the primary premature ejaculation group, and if more than one volunteer was eligible at the same time, the one with the closest age was selected； * patient does not meet the 2014 international society for sexual medicine (issm) criteria for defining premature ejaculation； * patients had a stable, heterosexual relationship with a single sexually active female partner for at least 6 months and with at least two sexual intercourses a week and kept stable during the study period; * patients had fully informed consent, signed informed consent form； exclusion criteria: * patients were diagnosed with secondary pe, variable pe, and subjective pe; * patients were using medications for endocrinological, metabolic, chronic systemic, or psychiatric diseases; * patients were abusing alcohol or illegal drugs； * patients were diagnosed with erectile dysfunction (ed) if their scores were \<21 on the abridged five-item international index of erectile function (iief-5) * patients were diagnosed with sexual hormone abnormalities, hyperthyroidism, hypothyroidism, peyronie's disease, prostatitis, urethritis, or urinary tract infection; * patients with head injuries that prevent them from completing near-infrared light brain function imaging * patients with severe schizophrenia, anxiety, depression or other neurological symptoms or poor compliance
applying prechtl's assessment of general movements for preterm infants through telemedicine

Conditions: Infant, Premature

Summary: the investigators will implement a study to evaluate the hypothesis that applying general movements assessments (gma) in a telemedicine setting with real-time scoring is feasible and comparable to scoring video recordings.

the investigators hypothesize that using telemedicine to conduct the gma will improve early identification of risk for cerebral palsy and facilitate earlier referral and access to neurodevelopmental intervention. preterm birth results from complex interactions of biological and socioeconomic risk factors, all of which continue to influence neurodevelopmental trajectories beyond the prenatal and neonatal period. unfortunately many of the socioeconomic factors that contribute to increased risk of prematurity are also associated with decreased likelihood to attend appointments at high risk infant follow-up (hrif) clinics. early intervention has been shown to be most beneficial to infants with highest social risk. additionally, mothers living in more rural communities tend to have higher social risk. they are often younger, more likely to be a single parent, and have lower income. helping make follow-up more accessible and convenient for families through telemedicine and at an earlier age using the gma has the potential to improve early identification, minimize loss to follow-up and ensure prompt referral to optimize outcomes for the most vulnerable babies in this already high-risk population.

Eligibility criteria:
inclusion criteria: * all preterm infants who meet the high-risk infant follow up (hrif) criteria (less than 32 weeks gestational age or birth weight less than 1500 grams) who are cared for at uc davis medical center exclusion criteria: * families who are non-english speakers requiring a translator * families who are unable to access data-capable wireless service to participate in telemedicine visits through zoom.